Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03442985 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of Palovarotene for the Treatment of MO
A Phase 2 study, sponsored by Clementia Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 193
- Enrollment target
NCT03442985: Clinical Trial Phase 2 study, sponsored by Clementia Pharmaceuticals.
NCT03442985 is a Phase 2 study that was terminated before completion, run by Clementia Pharmaceuticals. The registered enrollment target is 193 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (45% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03442985, a Phase 2 study, was terminated before completion, sponsored by Clementia Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 193 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled study comparing the safety and efficacy of 2 dosage regimens of palovarotene versus placebo in preventing disease progression in pediatric subjects with multiple osteochondromas (MO).
Primary Outcome
The annualized rate of new OCs was assessed by whole-body magnetic resonance imaging (MRI) (that is, the total number of new OCs divided by the time in years between the baseline and latest post-baseline MRI).
Interventions
- OTHER Placebo
- DRUG Palovarotene 2.5 mg
- DRUG Palovarotene 5.0 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2018-03-22 |
| Est. Completion | 2020-10-30 |
| Phase | Phase 2 |
Why NCT03442985 stopped before completion
NCT03442985 is an interventional study that assigns participants to a tested intervention. The registered 193 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (45% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03442985 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03442985 about?
NCT03442985 is a clinical study titled "An Efficacy and Safety Study of Palovarotene for the Treatment of MO". This is a randomized, double-blind, placebo-controlled study comparing the safety and efficacy of 2 dosage regimens of palovarotene versus placebo in preventing disease progression in pediatric subjects with multiple osteochondromas (MO).
What is the current status of trial NCT03442985?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 193 participants. The study started on 2018-03-22. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT03442985?
The interventions under investigation include: Placebo (OTHER), Palovarotene 2.5 mg (DRUG), Palovarotene 5.0 mg (DRUG).
Who is sponsoring clinical trial NCT03442985?
This trial is sponsored by Clementia Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03442985's enrollment target sits among peer trials
193 352nd of 2000 higher than 1,649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06226220 · 193 participants · NA
Percutaneous Nerve Evaluation Trial Time
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI